Updated APHINITY Supports Benefit of Dual HER2 Blockade Updated APHINITY Supports Benefit of Dual HER2 Blockade

A new analysis some 6 years after randomization continues to support dual HER2 blockade plus chemotherapy for HER2-positive early breast cancer.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news